Knowledge
check

Test your knowledge on the appropriate prescribing of antibiotics using our knowledge quiz

Alt tag
References
  • Wirz Y, Meier MA, Bouadma L, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. Crit Care 2018; 22: 191. Return to content
  • Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis 2018; 18: 95–107. Return to content

MA-PF-AI-SG-0004-1. Date of preparation, February 2021.

References
  • Cherazard R, Epstein M, Doan T-L, et al. Antimicrobial resistant Streptococcus pneumoniae: prevalence, mechanisms, and clinical implications. Am J Ther 2017; 24: e361–9. Return to content
  • Schroeder MR, Stephens DS. Macrolide resistance in Streptococcus pneumoniae. Front Cell Infect Microbiol 2016; 6: 98. Return to content
  • Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40: 1288–97. Return to content
  • Liñares J, Ardanuy C, Pallares R, et al. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30 year period. Clin Microbiol Infect 2010; 16: 402–10. Return to content
  • Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90: 223–9. Return to content
  • Jones ME, Bloser-Middleton RS, Crtichley IA, et al. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenza and Moraxella catarrhalis: a European multicenter study during 2000–2001. Clin Microbiol Infect 2003; 9: 590–9. Return to content
  • Bidell MR, Pai MAP, Lodise TP. Use of oral tetracyclines in the treatment of adult patients with community-acquired bacterial pneumonia: a literature review on the often-overlooked antibiotic class. Antibiotics 2020; 9: 905. Return to content

MA-PF-AI-SG-0004-1. Date of preparation, February 2021.

References
  • Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200: e45–7. Return to content
  • Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27–S72. Return to content
  • Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40: 1288–97. Return to content
  • Plouffe JE. Importance of atypical pathogens of community-acquired pneumonia. Clin Infect Dis 2000; 331 (Suppl 2): S35–9. Return to content

MA-PF-AI-SG-0004-1. Date of preparation, February 2021.

References
  • Montravers P, Bassetti M. Curr Opin Infect Dis 2018; 31: 587–93. Return to content
  • Bassetti M, Vena A, Castaldo N, et al. Curr Opin Infect Dis 2018; 31: 177–86. Return to content
  • Torres A, Rank D, Melnick D, et al. Open Forum Infect Dis 2019; 6: ofz149. Return to content

MA-PFM-AI-SG-0009-1. Date of preparation, October 2020.

References
  • Roquilly A, Marret E, Abraham E, et al. Clin Infect Dis 2015; 60: 64–75. Return to content
  • Klompas M, Branson R, Eichenwald EC, et al. Infect Control Hosp Epidemiol 2014; 35: 915–36. Return to content
  • Muscedere J, Rewa O, McKechnie K, et al. Crit Care Med 2011; 39: 1985–91. Return to content

MA-PFM-AI-SG-0009-1. Date of preparation, October 2020.

References
  • Moberley S, Holden J, Tatham DP, et al. Cochrane Database Syst Rev 2013; 1: CD000422. Return to content
  • Huss A, Scott P, Stuck AE, et al. CMAJ. 2009; 180: 48–58. Return to content
  • Johnstone J, Eurich DT, Minhas JK, et al. Clin Infect Dis 2010; 51: 15–22. Return to content
  • Rosén C, Christensen P, Hovelius B, et al. Acta OtoLaryngol 1984; 98: 524–32. Return to content

MA-PFM-AI-SG-0009-1. Date of preparation, October 2020.

If you have observed any unwanted or adverse effect, or have a quality complaint related to a Bayer product, we would be interested to hear about it as part of our ongoing pharmacovigilance processes. You may report these to us through our Bayer Side Effect Reporting website.